Unicycive Therapeutics (UNCY) stock
Follow UNCY's news. Members get an alert when Unicycive Therapeutics files news, and see its trials, share raises, and its CEO's filings.
What's next for UNCY, and how long its cash lasts
From Unicycive Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words and the arithmetic, not a forecast. Companies often miss their own dates.
Cash runway
About 8 quarters
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first.
Why it's down
Down 40% in 3 months, 10% under its 50-day average.
Down more than its industry: the 259 other stocks in it fell a median 11% over the same 3 months.
−1Long-term trend below a falling 200-day
2 more things pulling UNCY's score down, for members
What's next
Expected to report Thu Nov 12, before the open
After its last 4 reports it closed +3.4% on average, higher 3 of 4 times.
What would turn UNCY's score around: 6 things, for members
Here is what members see.
Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.
UNCY has 1 of 14 checks firing
One per group is shown here.
How UNCY ranks in Biotech
UNCY is #182 of 260 by Quality Score. The top three are shown with their scores, and the rest by name.
PBYI10/1419
ABCL9/1419
RGEN7/1419
AMRXOpen for its score
EXELOpen for its score
UNCY1/14-2
When does UNCY report, and what happens after?
Expected to report Thu Nov 12, before the open (in 44 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 12, 2026Before open | Before open | +2.8% | +7.8% | +12.6% |
| May 12, 2026Before open | Before open | 0.0% | +2.8% | +2.5% |
| Mar 30, 2026Before open | Before open | -3.6% | -4.4% | +3.6% |
| Nov 12, 2025Before open | Before open | +0.2% | +7.3% | +23.6% |
About Unicycive Therapeutics
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of UNCY's score, with the points and the reason
- All 14 checks on UNCY and on all 2,952 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on UNCY
Straight Answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week traits rest on real history. Options flow is not part of the product.
What does it cost?
Nothing for the first 8 days. After that, one plan with everything in it, only if you choose to subscribe: $29 a month, $69 for three months, or $249 a year. Payments go through Stripe, so Breakaway never sees your card.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.